| Overview |
| bs-23765R-PE |
| FPRL1 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FPRL1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2358 |
| P25090 |
| ALXR; FMLP R I; FMLP R II; FMLP related receptor I; FMLP-R-I; FMLP-R-II; FMLP-related receptor I; FMLPX; Formyl peptide receptor 2; Formyl peptide receptor like 1; Formyl peptide receptor related; Formyl peptide receptor-like 1; FPR 2; FPR2; FPR2_HUMAN; FPR2A; FPRH 1; FPRH 2; FPRH1; FPRH2; FPRL 1; FPRL1; HM63; Lipoxin A4 receptor; LXA4 receptor; LXA4R; N-formyl peptide receptor 2; RFP. |
| FPRL1 is a low affinity receptor to N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of proinflammatory signals such as LTB4 (leukotriene B4). FPRL1 has been reported in phagocytes, monocytes, neutrophils, differentiated myeloid cells from bone marrow, granulocyte HL-60 cells, and synovial fibroblasts. ESTs have been isolated from blood, leukocyte, lung, and placenta libraries. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz